Medizinische Universität Graz - Research portal
Daga Shruti |
** = Publications listed in SCI/SSCI/Pubmed
2020
Full paper/article (Journal)
** Daga, S; Rosenberger, A; Kashofer, K; Heitzer, E; Quehenberger, F; Halbwedl, I; Graf, R; Krisper, N; Prietl, B; Höfler, G; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
Am J Hematol. 2020; 95(10):1148-57
Doi: 10.1002/ajh.25918
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Full paper/article (Journal)
** Daga, S; Rosenberger, A; Quehenberger, F; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wölfler, A
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Cancer Med. 2019; 8(4):1771-1778
Doi: 10.1002/cam4.2053
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2018
Full paper/article (Journal)
** Gaksch, L; Kashofer, K; Heitzer, E; Quehenberger, F; Daga, S; Hofer, S; Halbwedl, I; Graf, R; Krisper, N; Hoefler, G; Zebisch, A; Sill, H; Wölfler, A
Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
Am J Hematol. 2018; 93(1):23-30
Doi: 10.1002/ajh.24922
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Journal)
** Daga, S; Rosenberger, A; Krisper, N; Prietl, B; Reinisch, A; Zebisch, A; Sill, H; Wolfler, A
GPR56 and CLL-1 (CLEC12A) as putative leukemic stem cell markers in CD34-positive acute myeloid leukemia
ONCOL RES TREAT. 2018; 41: 73-73.
[Poster]
Web of Science
2017
Abstract (Journal)
** Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Hofler, G; Zebisch, A; Sill, H; Wolfler, A
Persistence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML
ONCOL RES TREAT. 2017; 40: 140-141.
[Oral Communication]
Web of Science
2016
Abstract (Journal)
** Gaksch, L; Kashofer, K; Heitzer, E; Daga, S; Hofer, S; Krisper, N; Höfler, G; Zebisch, A; Sill, H; Wölfler A
Persitence of non-DNMT3A mutations predicts relapse in cytogenetically normal AML.
Oncol Res Treat 2016. 2016; 39(suppl3):140--Jahrestagung DGHO; OCT 14-18,2016; Leipzig. (ISBN: 2296-5270 )
[Oral Communication]
Web of Science